Khava I E Ibragimova
Overview
Explore the profile of Khava I E Ibragimova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geurts S, Ibragimova K, Ding N, Meegdes M, Erdkamp F, Heijns J, et al.
Breast Cancer Res Treat
. 2024 Feb;
205(2):287-302.
PMID: 38381274
Purpose: The aim was to determine whether the real-world first-line progression-free survival (PFS) of patients diagnosed with de novo human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer...
2.
Ibragimova K, Geurts S, Laczko D, Meegdes M, Erdkamp F, Heijns J, et al.
Clin Breast Cancer
. 2023 Nov;
24(2):103-111.
PMID: 38007349
Background: This study aims to explore whether first-line pertuzumab use modifies the effect of prior use of (neo-) adjuvant trastuzumab on the PFS of first-line HER2-targeted therapy in patients with...
3.
Ibragimova K, Geurts S, Meegdes M, Erdkamp F, Heijns J, Tol J, et al.
Breast Cancer Res Treat
. 2023 Jan;
198(2):239-251.
PMID: 36635428
Purpose: We assessed the systemic treatment choices and outcomes in patients diagnosed with human epidermal growth factor receptor-2-positive (HER2 +) advanced breast cancer (ABC), for the first four lines of...
4.
Meegdes M, Ibragimova K, Lobbezoo D, Vriens I, Kooreman L, Erdkamp F, et al.
Breast Cancer Res Treat
. 2022 Jan;
192(2):331-342.
PMID: 35025003
Purpose: The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the...
5.
Schmitz R, Geurts S, Ibragimova K, Tilli D, Tjan-Heijnen V, de Boer M
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771434
New treatment options in cancer have resulted in increased use of health care resources near the end of life. We assessed health care use near the end of life of...
6.
Ibragimova K, Geurts S, Croes S, Erdkamp F, Heijns J, Tol J, et al.
Breast Cancer Res Treat
. 2021 Mar;
188(2):571-581.
PMID: 33743103
Purpose: Immediate and proper implementation of a new and more potent therapy is important to ensure that the patient achieves the best possible outcome. This study aimed to examine whether...
7.
Claessens A, Ibragimova K, Geurts S, Bos M, Erdkamp F, Tjan-Heijnen V
Crit Rev Oncol Hematol
. 2020 Jun;
153:102988.
PMID: 32599374
This review aims to evaluate the role of chemotherapy-containing regimens in the treatment of advanced breast cancer (ABC), with the purpose to optimize selection, sequencing and duration of treatment with...
8.
Schneider P, Pouwels X, Passos V, Ramaekers B, Geurts S, Ibragimova K, et al.
PLoS One
. 2020 Apr;
15(4):e0230909.
PMID: 32271794
Objective: In breast cancer patients, treatment at the end of life accounts for a major share of medical spending. However, little is known about the variability of cost trajectories between...